LondamocitinibLondamocitinib
MedChemExpress (MCE)
HY-126294
2241039-81-4
AZD4604
JAK1-IN-7
98.98%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Londamocitinib (AZD4604) is a potent and selective JAK1 inhibitor with IC50 at 0.54 nM. Londamocitinib has anti-inflammatory activity.
Londamocitinib inhibits the phosphorylation of STAT6 in U937 cells induced by IL-4 or IL-13 (IC50 are 24 and 34 nM, respectively)[2].
Londamocitinib (1 mg/kg, intravenous injection, single dose) can reduce the phosphorylation of STAT3 and STAT5 in the lung of obumin-induced asthmatic rats, inhibit pulmonary eosinophilia, and reduce advanced asthma response in the same model[3].
JAK1 0.54 nM (IC50)
| | | |
| | | | | |
[1]. NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.
[2]. Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12
66(19):13400-13415. [Content Brief]
[3]. Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31
16:2901-2917. [Content Brief]